EGFR and non-small cell lung carcinoma: While prior studies have observed intra-patient heterogeneity of resistance mechanisms in ∼5–15% of EGFR mutant NSCLC patients10, 11, 23, 24, we found evidence for multiple resistance mechanisms in 46% of T790M-mutant patients.